Evidence map›Paper›PMID 42079140›Full record

ArticlebioRxiv : the preprint server for biology2026

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Alexis Talbot, Ke Li, Jae Hyun J Lee, Shanshan Lang, Chang Liu, Nechama Kalter, Zhongmei Li, Yasaman Mortazavi, Niran Almudhfar, Joseph J Muldoon and 27 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Alexis TalbotDepartment of Medicine, University of California San Francisco, CA, USA.
Ke LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Jae Hyun J LeeGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Shanshan LangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Chang LiuDepartment of Medicine, University of California San Francisco, CA, USA.
Nechama KalterThe Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 5290002, Israel.
Zhongmei LiDepartment of Medicine, University of California San Francisco, CA, USA.
Yasaman MortazaviGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Niran AlmudhfarGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Joseph J MuldoonDepartment of Medicine, University of California San Francisco, CA, USA.
Vincent AllainDepartment of Medicine, University of California San Francisco, CA, USA.
William NybergDepartment of Medicine, University of California San Francisco, CA, USA.
Jing-Yi J ChungDepartment of Medicine, University of California San Francisco, CA, USA.
Charlotte WangDepartment of Medicine, University of California San Francisco, CA, USA.
Zhongxia QiDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Netravathi KrishnappaInnovative Genomics Institute, Berkeley, CA, USA.
Alvin S HaDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Dehui KongDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Derrick HouserDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Sreenivasan ParuthiyilDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Moloud AhmadiThermo Fisher Scientific, Carlsbad, CA, USA.
Yongchang JiThermo Fisher Scientific, Carlsbad, CA, USA.
Michael RosenbergThe Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 5290002, Israel.
Luis A AcevedoDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Brianna LiangDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Kevin BrisenoDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
Serena S KwekDepartment of Medicine, University of California San Francisco, CA, USA.
Stefanie BachlDepartment of Medicine, University of California San Francisco, CA, USA.
Carter ChingDepartment of Medicine, University of California San Francisco, CA, USA.
Julia CarnevaleDepartment of Medicine, University of California San Francisco, CA, USA.
Petros GiannikopoulosDepartment of Laboratory Medicine, University of California San Francisco, CA, USA.
David Y OhDepartment of Medicine, University of California San Francisco, CA, USA.
Alexander MarsonDepartment of Medicine, University of California San Francisco, CA, USA.
Ayal HendelThe Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 5290002, Israel.
Thomas MartinDepartment of Medicine, University of California San Francisco, CA, USA.
Justin EyquemDepartment of Medicine, University of California San Francisco, CA, USA.
Brian R ShyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.

Funding

Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.K08CA252605 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARNEVALE, JULIA C · 2020 to 2024
$1.3M
Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturingK08CA273529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian R Shy · 2022 to 2026
$1.2M
NCATS NIH HHS L30 TR002983NCI NIH HHS K08 CA252605NCI NIH HHS K08 CA273529NIGMS NIH HHS T32 GM136547
6 · The paper itself

Abstract

Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by bone marrow infiltration, monoclonal immunoglobulin production, and microenvironmental dysregulation that leads to systemic organ damage. The advent of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has induced unprecedented responses and durability for patients with relapsed/refractory MM. These outcomes are rarely observed with prior salvage strategies, although relapse remains the predominant long-term challenge for most patients. The two currently approved BCMA CAR-T cell products use viral vectors to semi-randomly insert the CAR gene, which results in heterogeneous genomic composition and variability in efficacy, safety, and product consistency. To address these challenges, we integrated targeted CRISPR genome engineering with precise CAR transgene insertion at the T-cell receptor alpha constant (

Indexed as

BCMACAR-TCRISPRimmunotherapymultiple myeloma

Identifiers

PMID42079140
PMCPMC13131766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.